The Academy of Managed Care Pharmacy (AMCP) and PRIME Education are conducting a survey to gauge AMCP members’ opinions on some possible solutions to breaking down barriers currently facing biologic therapies.
According to AMCP, the survey is being funding through a grant from Sandoz.
While the Biologics Price Competition and Innovation Act of 2009 created a streamlined approval pathway for biologics, adoption and cost savings have “fallen short of expectations,” AMCP says. The FDA since 2015 has approved 12 biosimilars.
“Major barriers to adopting biosimilars include concerns about their safety and efficacy, contracting and pricing dynamics, and evolving regulatory guidance on interchangeability and substitution with reference biologics,” AMCP said in an email.
To find out more about the survey, click here.